December 18, 2019 / 8:29 PM / 8 months ago

BRIEF-Abbvie Reaches Agreement With PCPA For Combination Venclexta With Rituximab As Treatment For Chronic Lymphocytic Leukemia

Dec 18 (Reuters) - Abbvie Inc:

* ABBVIE REACHES AN AGREEMENT WITH THE PAN-CANADIAN PHARMACEUTICAL ALLIANCE (PCPA) FOR THE COMBINATION VENCLEXTA® WITH RITUXIMAB AS A TREATMENT FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

* ABBVIE INC - VENCLEXTA CONTINUES TO BE INVESTIGATED IN CLL AND OTHER HEMATOLOGICAL DISEASES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below